The Omega-3 fatty acid docosahexaenoic acid modulates inflammatory mediator release in human alveolar cells exposed to bronchoalveolar lavage fluid of ards patients by Cotogni, Paolo et al.
Research Article
The Omega-3 Fatty Acid Docosahexaenoic Acid Modulates
Inflammatory Mediator Release in Human Alveolar Cells
Exposed to Bronchoalveolar Lavage Fluid of ARDS Patients
Paolo Cotogni,1 Antonella Trombetta,2 Giuliana Muzio,3
Marina Maggiora,3 and Rosa Angela Canuto3
1Anesthesiology and Intensive Care, Department of Medicine, S. Giovanni Battista Hospital, University of Turin,
Via A.M. Dogliotti 14, 10126 Turin, Italy
2Department of Medical Sciences, University of Turin, Via A.M. Dogliotti 14, 10126 Turin, Italy
3Department of Experimental Medicine and Oncology, University of Turin, Corso Raffaello 30, 10125 Turin, Italy
Correspondence should be addressed to Paolo Cotogni; paolo.cotogni@unito.it
Received 12 October 2014; Accepted 28 January 2015
Academic Editor: Karsten Weylandt
Copyright © 2015 Paolo Cotogni et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. This study investigated whether the 1 : 2𝜔-3/𝜔-6 ratio may reduce proinflammatory response in human alveolar cells
(A549) exposed to an ex vivo inflammatory stimulus (bronchoalveolar lavage fluid (BALF) of acute respiratory distress syndrome
(ARDS) patients).Methods. We exposed A549 cells to the BALF collected from 12 ARDS patients. After 18 hours, fatty acids (FA)
were added as docosahexaenoic acid (DHA, 𝜔-3) and arachidonic acid (AA, 𝜔-6) in two ratios (1 : 2 or 1 : 7). 24 hours later, in
culture supernatants were evaluated cytokines (TNF-𝛼, IL-6, IL-8, and IL-10) and prostaglandins (PGE
2
and PGE
3
) release. The
FA percentage content in A549 membrane phospholipids, content of COX-2, level of PPAR𝛾, and NF-𝜅B binding activity were
determined. Results.The 1 : 2 DHA/AA ratio reversed the baseline predominance of 𝜔-6 over𝜔-3 in the cell membranes (P < 0.001).
The proinflammatory cytokine release was reduced by the 1 : 2 ratio (P < 0.01 to <0.001) but was increased by the 1 : 7 ratio (P < 0.01).
The 1 : 2 ratio reduced COX-2 and PGE
2
(P < 0.001) as well as NF-𝜅B translocation into the nucleus (P < 0.01), while it increased
activation of PPAR𝛾 and IL-10 release (P < 0.001). Conclusion. This study demonstrated that shifting the FA supply from 𝜔-6 to 𝜔-3
decreased proinflammatory mediator release in human alveolar cells exposed to BALF of ARDS patients.
1. Introduction
Acute respiratory distress syndrome (ARDS) is a form of
acute diffuse lung injury associated with a predisposing risk
factor, characterized by inflammation leading to increased
pulmonary vascular permeability and loss of aerated lung
tissue [1]. According to the Berlin definition, the acute
phase of this syndrome is manifested by the early onset of
respiratory failure (within 1 week of a known clinical insult
or new/worsening respiratory symptoms) [2].Themain char-
acteristic of the clinical syndrome is hypoxemia; specifically,
each subcategory of ARDS (mild, moderate, and severe) is
defined bymutually exclusive ranges of the ratio between par-
tial pressure of arterial oxygen (PaO
2
) and fraction of inspired
oxygen (FiO
2
) (200mmHg < PaO
2
/FIO
2
≤ 300mmHg,
100mmHg < PaO
2
/FIO
2
≤ 200mmHg, and PaO
2
/FIO
2
≤
100mmHg, resp.) [2]. Mortality from severe ARDS in the
1970s was as high as 85–90% but, from 2000, it decreased to
20–40% [3].
In the ARDS early phase, the alveolar space is char-
acterized by alveolar infiltration with neutrophils and
macrophages, and both are able to release inflammatory
cytokines with an accumulation of both proinflammatory
and anti-inflammatory cytokines [4, 5]. Many cytokines were
detected at elevated levels in bronchoalveolar lavage fluid
(BALF) in patients with ARDS, that is, tumor necrosis factor
(TNF)-𝛼, interleukin (IL)-1𝛽, IL-6, and IL-8. The key role
of a hyperinflammatory response, mainly characterized by
the overproduction of proinflammatory cytokines, in the
progression of the lung damage is well-documented [6, 7].
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Moreover, many studies reported an increased mortality
in patients who have elevated proinflammatory cytokine
concentrations (TNF-𝛼, IL-6, and IL-8) in the BALF at the
onset of ARDS or persistent increased concentrations [8, 9].
Similarly, low levels of anti-inflammatory cytokines (i.e., IL-
10 and IL-1 receptor antagonist) in the BALF in the ARDS
early phase are associated with an increased mortality [10,
11]. Thus, the balance between proinflammatory and anti-
inflammatory cytokines is of greater importance because the
degree of cytokine imbalance is a contributing element to
ARDS severity [12].
Over the last years, there has been an improving under-
standing of polyunsaturated fatty acid (PUFA) pathophysi-
ology and several mechanisms for the interaction between
PUFAs and inflammation or immune response have been
demonstrated [13–16]. Indeed, after PUFA supply (diet or
enteral and parenteral administration), many cell properties
and related functions are modified, mainly the inflammatory
and immunity responses [13]. Briefly, omega- (𝜔-) 3 PUFAs
are more regarded as anti-inflammatory agents, whereas 𝜔-
6 PUFAs are regarded as proinflammatory agents. Recently,
it was speculated that 𝜔-3 PUFAs may be involved in the
resolution of inflammation [14].
The discovered ability of 𝜔-3 PUFAs to downregulate
several different responses of the inflammatory process had
suggested that these PUFAs might be used not exclusively
as nutrients but mainly as pharmacological agents. Since
the 1990s, many editorials have stressed the possibility to
modulate the inflammatory response in acute lung injury
(ALI) or ARDS patients using 𝜔-3 PUFAs as drugs (the so-
called “pharmaconutrition”) [17–19]. Subsequently, a great
number of studies with cell or animal models have been
carried out with the aim to demonstrate the efficacy of fish
oil or their main active components (i.e., eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA)) in modifying
the inflammatory responses [20–22]. Likewise, there have
been several randomized controlled trials of enteral [23–28]
or parenteral [5, 29–31] administration of fish oil-enriched
nutrition formulas in mechanically ventilated patients with
ALI, ARDS, or sepsis.
In a previous study [32], we demonstrated that shifting
the PUFA supply from 𝜔-6 PUFA (i.e., arachidonic acid
(AA)) to 𝜔-3 PUFA (i.e., DHA) significantly reduced the
release of proinflammatory cytokines in human alveolar cells
undergoing lipopolysaccharide (LPS) challenge. Moreover,
we found that, in the presence of a DHA/AA ratio with a
predominance of AA, there was a cytokine balance more
oriented towards a proinflammatory response than with LPS
alone. The aim of this study was to investigate whether in
human alveolar cells the 1 : 2 DHA/AA ratio was effective in
reducing proinflammatory response induced by an ex vivo
inflammatory stimulus such as BALF of ARDS patients.
2. Materials and Methods
2.1. Bronchoalveolar Lavage Fluid Collection. The BALF was
collected from ARDS patients—requiring mechanical venti-
lation and BAL for clinical purposes—within 24 hours after
endotracheal intubation and stored at −80∘C as previously
described [33]. The selection of ARDS patients was carried
out as previously described [34]. The institutional review
board approved the study.
2.2. Cell Culture and Treatment. The human lung carcinoma
cell line A549 (ATCC, Rockville, MD, USA) was used.
A549 are alveolar epithelial cells with type II pneumocyte
properties. The A549 were cultured in HAM-F12 K medium
(Sigma-Aldrich, St Louis,MO,USA) and treated as previously
described [35].
BALF was added 24 hours after seeding, while LPS
(400 𝜇g/mL) was used as positive control. After 18 hours,
A549 cells were treated with 50𝜇M of 1 : 2 DHA/AA ratio
(DHA 17 𝜇Mplus AA 33 𝜇M) or 50 𝜇Mof 1 : 7 DHA/AA ratio
(DHA 6.5 𝜇M plus AA 43.5 𝜇M) for 24 hours. PUFAs and
LPS from Escherichia coli 055:B5 were obtained from Sigma-
Aldrich.
2.3. ELISA. At the experimental end point (i.e., after 24
hours), cytokine contents were measured in BALF (i.e., IL-
1𝛽, TNF-𝛼, IL-6, and IL-8) and in culture supernatants
(i.e., TNF-𝛼, IL-6, IL-8, and IL-10) via enzyme-linked
immunosorbent assay (ELISA). Cytokine kits were purchased
from Euroclone (Paignton-Devon, UK). Prostaglandins E
2
and E
3
(PGE
2
and PGE
3
) release was measured in culture
supernatants via ELISA. Prostaglandin kits were purchased
from MyBioSource (San Diego, CA, USA). The assays were
performed according to the manufacturer’s instructions.
2.4. Fatty Acid Percentage Content in Membrane Phospho-
lipids. At the experimental end point, the fatty acid (FA)
percentage content was determined as previously described
[36]. Briefly, total lipids were extracted by the method of
Folch et al. [37] and separated by thin-layer chromatography
using n-heptane : isopropylether : formic acid (90 : 60 : 3) as
solvent. Phospholipids bands (deposition line) were scraped,
extracted, and used for FA determination. FA methyl esters
were prepared following the method of Metcalfe et al.
[38] and separated by gas-liquid chromatography (CP 9002
Chrompack International B.V., Middelburg, Netherlands).
Internal standard (methyl heptadecanoate) was added to each
preparation to determine recovery.
2.5. Preparation of Total Cell Lysate for Western Blot Analysis.
Total cells lysates were obtained as previously described
[35]. Briefly, cells were sonicated in HCMF buffer con-
taining 1% Triton, 0.1% SDS, 2mM Calcium Chloride
(CaCl
2
), 100 𝜇g/mL phenylmethylsulfonyl fluoride (PMSF),
and 1 𝜇g/mL leupeptin at an intermediate setting (output ≅
3) using a Branson Sonifier 250 (VWR Scientific, OH, USA).
Lysates were cooled on ice for 3–5min and the sonicating–
cooling cycle was repeated for a total of 3 cycles.
2.6. Preparation of Cytoplasmic and Nuclear Extracts for
Western Blot Analysis. At the experimental end point, culture
media were collected and stored at −80∘C until cytokine
concentration evaluation with ELISA and cells were lysed for
cytoplasmic and nuclear protein fractions extraction. Briefly,
cells were lysed into buffer A (10mM HEPES pH 7.9, 10mM
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Figure 1: BALF cytokine pattern in ARDS. (a) IL-1𝛽 and TNF-𝛼 proinflammatory cytokine content in BALF collected from pulmonary
(ARDSp, white bars) and extrapulmonary (ARDSexp, black bars) ARDS patients. (b) IL-6 and IL-8 cytokine content in BALF collected from
pulmonary (ARDSp, white bars) and extrapulmonary (ARDSexp, black bars) ARDS patients. The results are expressed as picograms (pg) or
nanograms (ng) of cytokines per mL as indicated. Data are presented as mean ± standard deviation of 12 independent determinations (𝑛 = 7
ARDSp and 𝑛 = 5 ARDSexp). BALF, bronchoalveolar lavage fluid; ARDS, acute respiratory distress syndrome; IL, interleukin; TNF, tumor
necrosis factor. ∗𝑃 < 0.05 ARDSp versus ARDSexp. ∗∗𝑃 < 0.01 ARDSp versus ARDSexp. ∗∗∗𝑃 < 0.001 ARDSp versus ARDSexp.
KCl, 0.1mM EDTA) added with 1mM DTT, 0.5mM PMSF,
5 𝜇L of 10 𝜇g/𝜇L of aprotinin, leupeptin, and pepstatin A
and 40 𝜇L/mL of IGEPAL 10%. Cell lysates were centrifuged
with a Microfuge at 15,000 rpm × 3min at 4∘C. Supernatants
cytoplasmic fractions were collected and stored at −80∘C
until use. Nuclei pellets were lysated, for 2 h at 4∘C, in buffer
B (20mM HEPES, pH 7.9, 0.4M NaCl, 1mM EDTA, and
10% glycerol) added with 1mM DTT, 0.5mM PMSF, 5 𝜇L
of 10 𝜇g/𝜇L of aprotinin, leupeptin, and pepstatin A. Nuclei
lysates were centrifuged with a Microfuge at 15,000 rpm ×
5min at 4∘C. Nuclei fractions were collected and stored at
−80∘C until use. HEPES, KCl, NaCl, EDTA, glycerol, DTT,
PMSF, aprotinin, leupeptin, pepstatin A, and IGEPAL were
purchased from Sigma-Aldrich.
2.7. Western Blot Analysis. Protein concentrations in the cell,
nuclei, and cytoplasmic extracts were measured using the
Protein Assay Kit 2 according to the manufacturer’s instruc-
tions (Bio-Rad Laboratories, Hercules, CA, USA). Thirty
micrograms of proteins from the cell or nuclei fractions were
separated by SDS-polyacrylamide gel electrophoresis using
10% polyacrylamide gel. Proteins were then transferred onto
polyvinylidene difluoride membranes (Immobilon-P, Milli-
pore, MA, USA). The membranes were blocked overnight
using 5% nonfat milk in 50mM Tris/150mM HCl (pH
7.5) containing 0.1% Tween 20 (TBS/Tween). After three
5-min rinses with TBS/Tween, membranes were probed
with polyclonal anti-PPAR𝛾, anti-COX-2, anti-p65 NF-𝜅B,
or anti-I𝜅B𝛼 (Santa Cruz Biotechnology, Heidelberg, Ger-
many) for 1 h at room temperature. After three 5-min rinses
withTBS/Tween, horseradish peroxidase- (HRP-) conjugated
secondary antibodies goat anti-rabbit or goat anti-mouse
IgG (Santa Cruz Biotechnology) were applied for 1 h at
room temperature. Protein bands were visualized using a
chemiluminescence detection system (Immun-Star HRP;
Bio-Rad Laboratories, Hercules, CA, USA). To normalize
protein signals, stripped PVDF membranes were reprobed
with monoclonal anti-𝛽-actin (Sigma-Aldrich) for cytosolic
and cell fractions or with polyclonal anti-lamin A/C (Santa
Cruz Biotechnology).
2.8. Statistical Analysis. Data were expressed as mean ±
standard deviation. Multiple comparisons were carried out
using one-way analysis of variance (ANOVA), followed by
Bonferroni post hoc test. SPSS statistical Software, version
14 (SPSS Inc, Chicago, IL, USA), was used for analyses.
Significance was defined as 𝑃 < 0.05.
3. Results and Discussion
3.1. BALF Cytokine Pattern in ARDS Patients. The BALF was
collected from twelve adult ARDS patients (9 males and 3
females; age 56 ± 4 yrs; pneumonia 𝑛 = 7 and sepsis 𝑛 =
5; Simplified Acute Physiology Score (SAPS) II 42 ± 18).
Proinflammatory cytokines IL-1 𝛽 and TNF-𝛼 were signif-
icantly higher in primary pneumonia patients (pulmonary
ARDS, ARDSp) than in patients with ARDS originating from
sepsis (extrapulmonary ARDS, ARDSexp) (Figure 1(a)). This
was also observed for IL-6 and, in particular, IL-8 content
(Figure 1(b)).
It has been extensively documented that in BALF of
ARDS patients the content of proinflammatory cytokines
is markedly elevated [12]. TNF-𝛼 and IL-1𝛽 are the main
proinflammatory cytokines and they are important in driving
the initial lung inflammatory response principally through
the stimulation of other cytokines (i.e., IL-6 and IL-8). IL-6
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occupies a critical place in modulating ARDS inflammatory
response, while chemokine IL-8 is the major neutrophil
chemotactic factor into the alveolar space and it is an early
marker for the development of ARDS [10]. In particular,
a high content of IL-6 and IL-8 is correlated with the
progression of lung injury as well as with a poor outcome
[8, 9].
There are many etiologic risk factors for ARDS, which
are generally divided into those associated with direct injury
(ARDSp) to the lung and those that cause indirect lung injury
(ARDSexp) in the setting of a systemic process [17, 39, 40].
Indeed, experimental and clinical studies showed little overall
differences in the inflammatory responses between direct and
indirect lung injury categories.Thus, identification of the risk
factor leading to ARDS in the single patient, regardless of its
direct or indirect nature, is rather useful to guide treatment
for the underlying disease causing ARDS [1]. Moreover,
clinical data supported the theory that an overaggressive and
persistent patient inflammatory response, rather than the
condition causing lung injury, is the most important factor
affecting survival in ARDS patients [41].
3.2. BALF of ARDS Patients Stimulates A549 Inflammatory
Response. In a previous study, we demonstrated that human
alveolar cells (A549) release proinflammatory cytokines
(TNF-𝛼, IL-6, and IL-8) in the culture medium when
challenged with a proinflammatory stimulus such as LPS,
suggesting that the alveolar epithelium has a role in the
hyperinflammatory response associated with ARDS [32].
Since LPS is an artificial stimulus, in this study we chal-
lenged A549 with BALF of ARDS patients. In this study,
BALF stimulation induced a proinflammatory response from
A549 cells as demonstrated by release of inflammatory
cytokines: TNF-𝛼 (Figure 2(a)), IL-6 (Figure 2(b)), and IL-8
(Figure 2(c)) while BALF did not elicit anti-inflammatory IL-
10 release (Figure 2(d)). These results demonstrated that the
pattern of cytokine release of A549 cells exposed to BALF is
similar to that elicited by LPS in the previous study.
3.3. Opposite Effects of DHA/AARatios on the Cytokine Release
from A549 Stimulated Cells. The nutrition support of ARDS
patients includes lipids, usually soybean or safflower oil-
based emulsions. These emulsions contain more than 50% of
linoleic acid (𝜔-6), a precursor of AA [42], while are deficient,
less than 10%, of 𝜔-3 PUFAs (mainly, 𝛼-linolenic acid).
Even though the beneficial effects of 𝜔-3 PUFA have been
extensively proven by plenty of experimental preclinical data,
conflicting results have been obtained fromboth clinical trials
and human intervention studies [15], in ARDS in particular
[28]. Therefore, the debate in the scientific community is still
open and a definitive accepted recommendation concerning
the use of 𝜔-3 fatty acids in ARDS is still lacking [42].
The observation that optimal 𝜔-3 administration was not
only dose-related but was also independently affected by
the 𝜔-3/𝜔-6 PUFA ratio has led many authors to focus the
attention on the 𝜔-3/𝜔-6 PUFA ratio in nutrition support to
modulate inflammation responses. Different 𝜔-3/𝜔-6 PUFA
ratios, from 1 : 1 to 1 : 4, have been proposed, but the question
of the most favorable 𝜔-3/𝜔-6 PUFA ratio in ARDS patients
is not definitely established [43].
In a previous study, we demonstrated that, by affect-
ing 𝜔-3/𝜔-6 ratio in phospholipids cell membranes with
1 : 1 and 1 : 2 DHA/AA (𝜔-3/𝜔-6) ratio supply, the balance
between proinflammatory and anti-inflammatory cytokines
was modulated, thus limiting the A549 LPS-induced hyper-
inflammatory response. Moreover, we found that ratios with
a 𝜔-6 prevalence (i.e., 1 : 4 and 1 : 7 DHA/AA) potentiated
the effect of LPS stimulus [32]. In the present study, we
investigated whether 1 : 2 DHA/AA ratio was similarly effec-
tive in reducing A549 proinflammatory response induced
by an ex vivo inflammatory stimulus such as BALF col-
lected from ARDS patients. The 1 : 2 ratio was preferred to
1 : 1 ratio because it could combine efficacy and decreased
risk of immunosuppressive effects. The results clearly indi-
cate that 1 : 2 DHA/AA treatment significantly reduced the
release of proinflammatory cytokines induced by BALF
challenge: TNF-𝛼 (Figure 2(a)), IL-6 (Figure 2(b)), and IL-8
(Figure 2(c)). Besides, we found that 1 : 2 DHA/AA treatment
was also associated with an increased release of the IL-10
(Figure 2(d)), a potent anti-inflammatory cytokine, confirm-
ing that 1 : 2 DHA/AA was able to modulate the balance
between proinflammatory and anti-inflammatory cytokines.
Finally, the 1 : 7 DHA/AA ratio significantly potentiated the
BALF inflammatory effects.
Several studies have identified two main key elements in
the pathogenesis of ARDS: the occurrence of an imbalance
between proinflammatory and anti-inflammatory cytokines
[12] and the persistent elevation of proinflammatory media-
tors [8]. These conditions lead to additional nonpulmonary
organ dysfunction which contributes to excess mortality
rates in intensive care units [33, 42]. Therefore, strategies
for limiting the intensity of lung inflammatory response are
of major importance for prognosis and therapy. However,
although some pharmacological strategies have proven to
be successful in animal studies, human translation of these
results has not been so effective on outcome [44].
3.4. Biochemical and Molecular Mechanisms Involved in Anti-
Inflammatory Effects of 𝜔-3 in BALF-Stimulated A549 Cells.
Over the last 25 years, the pathophysiology and pharmacol-
ogy of 𝜔-3 PUFA have been continuously under scrutiny.
These FA are able to partly inhibit a number of aspects of
inflammation including eicosanoid and cytokine production
and bioavailability. The PUFA capacity to modulate different
signaling pathways involved in inflammation response has
been extensively studied in both physiological and patholog-
ical conditions [14, 16]. The main mechanisms explaining the
PUFA role in inflammation and investigated in this study
were graphically represented in Figure 3: effects on phospho-
lipid composition of A549 cell membranes, modulation of
eicosanoid and cytokine biosynthesis and release, and effects
on inflammatory signaling transcription pathways.
3.4.1. Eicosanoid Synthesis. The modulation of eicosanoid
production is driven by modification of the FA composi-
tion of the phospholipids within cell membranes. PUFAs
are rapidly incorporated into cell membrane phospholipids;
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Figure 2: Effects of 𝜔-3/𝜔-6 PUFA ratios on BALF induced cytokine release from A549 cells. (a) TNF-𝛼 proinflammatory cytokine release
from A549 cells, stimulated with BALF and treated with 1 : 2 and 1 : 7 DHA/AA PUFA ratios. (b) IL-6 proinflammatory cytokine release from
A549 cells stimulated with BALF and treated with 1 : 2 and 1 : 7 DHA/AA (𝜔-3/𝜔-6) PUFA ratios. (c) IL-8 proinflammatory cytokine release
fromA549 cells stimulated with BALF and treated with 1 : 2 and 1 : 7 DHA/AAPUFA ratios. (d) IL-10 anti-inflammatory cytokine release from
A549 cells stimulated with BALF and treated with 1 : 2 and 1 : 7 DHA/AA PUFA ratios. In each panel, data are presented as picograms (pg) of
the indicated cytokine per million cells. Data are presented as mean ± standard deviation of 12 independent determinations (𝑛 = 12). PUFA,
polyunsaturated fatty acid; BALF, bronchoalveolar lavage fluid; TNF, tumor necrosis factor; DHA, docosahexaenoic acid; AA, arachidonic
acid; IL, interleukin; LPS, lipopolysaccharide. ∗∗∗𝑃 < 0.001 1 : 2 DHA/AA versus all. ∗∗𝑃 < 0.01 1 : 2 DHA/AA versus all. ##𝑃 < 0.01 1 : 7
DHA/AA versus LPS and BALF.
moreover, the esterification of 𝜔-3 FAs is mainly at the
expense of 𝜔-6 AA [14]. Membrane phospholipids PUFAs
are precursors of eicosanoids, which are the biologically
active lipid mediators of inflammation playing wide ranging
roles in inflammation and in regulation of immune function
[14]. Eicosanoids originated from AA 𝜔-6 PUFA (2-series
prostaglandins (PGs) and 4-series leukotrienes (LTs)) have
proinflammatory properties while eicosanoids formed from
EPA and DHA 𝜔-3 PUFA (3-series PGs and 5-series LTs)
are less active and potentially anti-inflammatory [14]. The
balance between proinflammatory and anti-inflammatory
eicosanoid synthesis determines the extent of inflammatory
reaction [19].
In our previous study, we demonstrated that at the
baseline the𝜔-3/𝜔-6 PUFA ratio inmembrane phospholipids
of A549 was 1 : 5 and that it can be changed by challenging
the cells with 1 : 1 or 1 : 2 DHA/AA ratios [32]. Here, we exam-
ined the DHA and AA content in membrane phospholipids
of A549 BALF-stimulated and challenged with 1 : 2 or 1 : 7
ratios DHA/AA (Figure 4). At baseline in A549 membrane
phospholipids the 𝜔-6 PUFA fraction is predominant, with
a 𝜔-3/𝜔-6 ratio of 1 : 5. Notably, cell treatment with both
DHA/AA ratios reduced the AA content in A549 membrane
phospholipids, but the 1 : 2 DHA/AA ratio also significantly
increased the DHA percentage content. The supply of 1 : 2
DHA/AA ratio reversed the baseline predominance of 𝜔-6
over 𝜔-3 in the 𝜔-3/𝜔-6 PUFA ratio in membrane phospho-
lipids of A549 cells.
Eicosanoid biosynthesis begun when an inflammatory
stimulus activates phospholipases, which are the enzymes
that cleave the fatty acid precursors from the membrane
phospholipids. Released PUFAs are then converted into
6 BioMed Research International
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Figure 3: Schematic representation of PUFA mechanism of action
in BALF-stimulated A549 cells. PUFAs, polyunsaturated fatty
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Figure 4: Effects of 𝜔-3/𝜔-6 PUFA ratios on the percentage
content of AA andDHA in A549membrane phospholipids. Relative
percentage content of AA (white bars) and DHA (black bars) in
phospholipids of A549 cell membranes stimulated with BALF and
treated with 50 𝜇M 1 : 2 or 1 : 7 DHA/AA PUFA ratios. Data are
presented as percentage content of AA and DHA in the membrane
phospholipids of unstimulated or stimulated A549 cells as indicated.
Data are presented as mean ± standard deviation of 4 independent
experiments (𝑛 = 4). PUFA, polyunsaturated fatty acid; AA, arachi-
donic acid; DHA, docosahexaenoic acid; BALF, bronchoalveolar
lavage fluid. ∗∗∗𝑃 < 0.001 BALF versus unstimulated. ∗∗𝑃 < 0.01
1 : 2 and 1 : 7 DHA/AA versus all. ###𝑃 < 0.001 versus all.
eicosanoids, mainly PGs and tromboxanes by cycloxygenases
(COXs) and LTs by lipoxygenases (LOXs) [14].
There are two COX isoforms: the COX-1 that is con-
stitutively expressed in almost all cells and the COX-2
that is induced in many cell types by a broad range of
proinflammatory agents [45].The COX-2, also known as PG-
endoperoxide synthase, is the key enzyme in PG synthesis
from AA.
To verify whether in our experimental model there was
a modulation of PG biosynthesis, we analyzed the content
of COX-2. The results indicated that in response to BALF
stimulus A549 cells increased by 2.5-fold the expression
of COX-2 (Figure 5(a)) and produce a significant amount
of PGE
2
(Figure 5(b)). Noteworthy, even if COX-2 is the
inducible form of COX, A549 cells express the enzyme
constitutively [46]. According to Yang et al. [46], we found
that this level of COX-2 expression was not associated with a
PG synthesis (Figure 5(b)) in unstimulated A549.
The 1 : 2 DHA/AA treatment significantly restored the
expression of the enzyme at the level of unstimulated cells
(Figure 5(a)). This effect was significantly associated with a
reduction of PGE
2
release and an induction of PGE
3
synthesis
(Figure 5(b)), suggesting that the enzyme was in an active
form. The 1 : 7 DHA/AA ratio induced a less significant
inhibitory effect on the COX-2 content and the PGE
2
synthe-
sis.Thedifferences inCOX-2 content could be correlatedwith
the PGE
2
-dependent amplification of the enzyme [45].These
results indicate that both 𝜔-3 and 𝜔-6 PUFAs reduce the
expression of COX-2 induced by inflammatory stimuli such
as BALF but with a different extent. These effects on PGE
2
content well correlated with the availability of AA substrate
into membrane phospholipids (Figure 4). Moreover, treat-
ment with 1 : 2 DHA/AA also induced a significant increase
in PGE
3
content, a less potent inflammatory PG.This finding
well correlated with the increased DHA content in A549
membrane phospholipids (Figure 4). Notably, PGE
3
is a less
potent inducer of COX-2 gene expression in fibroblasts and of
IL-6 production by macrophages compared with PGE
2
[13].
In accordance with Yang et al.’s data [46], our results confirm
that exposure of alveolar cells to 𝜔-3 PUFA determines a
decrease in the COX-2-mediated formation of PGE
2
and an
increase in the level of PGE
3
.
3.4.2. Inflammatory Signaling Transcription Pathways: NF-𝜅B
andPPAR𝛾. Thenuclear factor (NF-𝜅B) is a key transcription
factor involved in upregulation of inflammatory cytokines,
adhesionmolecules, andCOX-2 genes [47]. Activation ofNF-
𝜅B transcription factor has been implicated in a number of
inflammation-related pathologies [14]. The p65 and p50 NF-
𝜅B heterodimers aremaintained inactive in the cytosol by the
binding with an inhibitory protein, namely, inhibitor of NF-
𝜅B (I𝜅B) [48]. Proinflammatory stimuli induce phosphoryla-
tion, ubiquitination, and proteasome mediated degradation
of I𝜅B, allowing NF-𝜅B translocation into the nucleus and
NF-𝜅B target gene transcription [48]. The inhibitory role of
𝜔-3 PUFAs onNF-𝜅B pathway has been demonstrated in sev-
eral experimental models and pathological conditions [19].
Different authors demonstrated that 𝜔-3 decreased TNF-𝛼
expression through the prevention of NF-𝜅B activation by
inhibiting I𝜅B phosphorylation and consequently preventing
NF-𝜅B translocation into the nucleus [14]. The correlation
between NF-𝜅B activation and cytokine content in BALF of
ARDS patients was previously demonstrated by Nys et al.
[49]. In order to understand the role of 1 : 2 DHA/AA
treatment on the NF-𝜅B pathway, we analyzed the expression
of p65NF-𝜅Bboth in the cytoplasmic and the nuclear fraction
of A549 BALF-stimulated cells (Figures 6(a) and 6(b)).
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Figure 5: Effects of𝜔-3/𝜔-6 PUFA ratios on PGE
2
andPGE
3
synthesis and release. (a) COX-2 relative protein content inA549 cells, stimulated
with BALF and treated with 50 𝜇M 1 : 2 and 1 : 7 DHA/AA PUFA ratios. Data are expressed as “a.u.” (arbitrary units) of the densitometric
values, normalized on the corresponding 𝛽-actin. The value of unstimulated cells was arbitrarily set as 100. Data are presented as mean ±
standard deviation of 6 independent determinations (𝑛 = 6). The image is representative of all the WB experiments. (b) PGE
2
(white bars)
and PGE
3
(black bars) content in culture media of A549 cells, stimulated with BALFs and treated with 50 𝜇M 1 : 2 or 1 : 7 DHA/AA ratio.
Data are presented as picograms (pg) of the indicated PG per mL. Data are presented as mean ± standard deviation of 12 independent
determinations (𝑛 = 12). PUFA, polyunsaturated fatty acid; PG, prostaglandin; COX, cycloxygenase; BALF, bronchoalveolar lavage fluid;
DHA, docosahexaenoic acid; AA, arachidonic acid; WB, western blot. ∗∗∗𝑃 < 0.001 BALF versus unstimulated cells and 1 : 2 DHA/AA.
∗∗
𝑃 < 0.01 1 : 7 DHA/AA versus all. ∗𝑃 < 0.05 1 : 2 DHA/AA versus unstimulated cells. ##𝑃 < 0.01 1 : 2 DHA/AA versus all.
The results demonstrated that 1 : 2 DHA/AA treatment
decreased NF-𝜅B content, in the nuclear fraction in partic-
ular, indicating an inhibition of its activation. The results
were confirmed by the finding that 1 : 2 DHA/AA treat-
ment increased the content of I𝜅B𝛼, one of the isoforms
of I𝜅B (Figure 6(c)). These results suggested that the anti-
inflammatory effects of 1 : 2 DHA/AA treatment were associ-
ated with the inhibition of the NF-𝜅B inflammatory pathway.
Since, genes of IL-1𝛽, IL-6, and TNF-𝛼, as well as COX-2, are
regulated by NF-𝜅B [50], we can speculate that the reduction
of proinflammatory cytokine release and the inhibition of
COX-2 expression were mediated by the inhibition of NF-𝜅B
transcriptional activity.
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated nuclear transcription factors encoded by
different genes. PPARs include 3 subtypes (𝛼, 𝛽, and 𝛾),
which are characterized by unique functions such as lig-
and specificities and tissue distribution [51]. PPAR ligands
encompass endogenous metabolites such as prostanoids and
PUFAs, as well as synthetic drugs such as fibrates and thiazo-
lidinediones. Inmacrophages, activation of PPAR𝛾negatively
influences the production of inflammatory cytokines like
TNF-𝛼, IL-6, and IL-1𝛽 [52]. It has been demonstrated that
most of the effects of PPARs on cytokine expression result
from crosstalk with other transcriptional factors and in par-
ticular with NF-𝜅B [53]. To verify if also in our experimental
model the anti-inflammatory effects of 𝜔-3 were correlated
with PPAR activation, we determined the PPAR𝛾 content
(Figure 7). The results indicated that the proinflammatory
stimulus was associated with the inhibition of PPAR𝛾 expres-
sion. Moreover, as we previously demonstrated [35], in the
present study we found both PUFA ratios were associated
with an increased PPAR𝛾 content but to a greater extent with
the 1 : 2 DHA/AA treatment.
Summarizing, we speculate that in our experimental
model the anti-inflammatory effects of 1 : 2 DHA/AA treat-
ment could be mediated by reduction of COX-2 expres-
sion, decrease of NF-𝜅B translocation into the nucleus, and
PPAR𝛾 activation. Thus, the results presented herein give
further insight into the mechanisms involved in the anti-
inflammatory effect of 𝜔-3 PUFAs.
3.4.3. Resolvins and Protectins. Recent studies have identified
n-3 PUFAs as precursors of a distinct set of lipid mediators
that probably act through distinct receptors to exert their
anti-inflammatory effects. These new n-3 PUFA-derived,
anti-inflammatory mediators have been named resolvins and
protectins. For an understanding of resolvin and protectin
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Figure 6: Effects of 𝜔-3/𝜔-6 PUFA ratios on NF-𝜅B. (a) p65 NF-𝜅B relative protein content in the cytoplasmic fraction of A549 cells,
stimulated with BALF and treated with 50 𝜇M 1 : 2 or 1 : 7 DHA/AA ratios. Data are expressed as “a.u.” (arbitrary units) of the densitometric
values, normalized on the corresponding𝛽-actin.The value of BALFwas arbitrarily set as 100.Data are presented asmean± standard deviation
of 6 independent determinations (𝑛 = 6). The image is representative of all the WB experiments. (b) NF-𝜅B relative protein content in
the nuclear fraction of A549 cells, stimulated with BALF and treated with 50𝜇M 1 : 2 or 1 : 7 DHA/AA ratios. Data are expressed as “a.u.”
(arbitrary units) of the densitometric values, normalized on the corresponding lamin A/C.The value of BALF was arbitrarily set as 100. Data
are presented as mean ± standard deviation of 6 independent determinations (𝑛 = 6). (c) I𝜅B𝛼 relative protein content in the cytoplasmic
fraction of A549 cells, stimulated with BALF and treated with 50𝜇M 1 : 2 or 1 : 7 DHA/AA ratios. Data are expressed as “a.u.” (arbitrary
units) of the densitometric values, normalized on the corresponding 𝛽-actin.The value of BALF was arbitrarily set as 100. Data are presented
as mean ± standard deviation of 6 independent determinations (𝑛 = 6). The image is representative of all the WB experiments. PUFA,
polyunsaturated fatty acid; NF-𝜅B, nuclear factor-kappa B; BALF, bronchoalveolar lavage fluid; DHA, docosahexaenoic acid; AA, arachidonic
acid; WB, western blot; I𝜅B, inhibitor of NF-𝜅B. ∗𝑃 < 0.05 1 : 2 DHA/AA versus all. ∗∗𝑃 < 0.01 1 : 2 DHA/AA versus all. ∗∗∗𝑃 < 0.001 1 : 2
DHA/AA versus all.
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PPAR𝛾 relative protein content in A549 cells stimulated with BALF
and treated with 50 𝜇M 1 : 2 or 1 : 7 DHA/AA ratios. Data are
expressed as “a.u.” (arbitrary units) of the densitometric values,
normalized on the corresponding𝛽-actin.The value of unstimulated
cells was arbitrarily set as 100. Data are presented asmean± standard
deviation of 6 independent determinations (𝑛 = 6). The image is
representative of all the WB experiments. PUFA, polyunsaturated
fatty acid; PPAR, peroxisome proliferator-activated receptor; BALF,
bronchoalveolar lavage fluid; DHA, docosahexaenoic acid; AA,
arachidonic acid; WB, western blot. ∗𝑃 < 0.05 BALF versus
unstimulated cells. ∗∗𝑃 < 0.01 1 : 7 DHA/AA versus BALF and
unstimulated cells. ∗∗∗𝑃 < 0.001 1 : 2 DHA/AA versus BALF and
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formation see Weylandt et al. [54] for a complete review.
Briefly, these lipid mediators might offer an important new
concept to explain the protective effect of n-3 PUFAs in a
wide variety of diseasemodels. In particular, DHAconstitutes
the origin for the D-series resolvins—mainly, resolvin D1
(RvD1)—as well as (neuro-) protectin D1.
In this study, we did not investigate resolvins or protectins
in our experimental model; however, previous experimental
studies showed that RvD1 had potent anti-inflammatory
effects in several disease models including lung injury. RvD1
could modulate the balance between proinflamatory and
anti-inflammatory cytokines, alter the response of the host to
pulmonary bacterial infection, and affect the early outcome
of infection [55]. Wang et al. showed that RvD1 improved
survival rate and attenuated ALI in mice induced by LPS;
specifically, RvD1 inhibited increases in TNF-𝛼 and IL-6
production in the BALF, reduced expression of COX-2, and
inhibited activation of NF-𝜅B [56].
4. Conclusions
ARDS is an inflammatory disease whose clinical severity
mostly depends on the grade of inflammation. Cytokines
and eicosanoids are key elements in the pathogenesis and
outcome of ARDS.
To the best of our knowledge, this is the first study
reporting the role of𝜔-3 to𝜔-6 PUFA ratio in themodulation
of release of four cytokines (TNF-𝛼, IL-6, IL-8, and IL-
10) and two prostaglandins (PGE
2
and PGE
3
) in human
alveolar cells exposed to BALF of ARDS patients. Differently
from our earlier study, the present study has some original
features. First, we challenged alveolar cells with an ex vivo
inflammatory stimulus and not with LPS. Second, the num-
ber of experiments was greater (12 versus 4). Third, we also
investigated the PG release as well as the content of COX-
2. Finally, we examined the more important inflammatory
signal transduction pathways (NF-𝜅B and PPAR𝛾) at work in
this experimental inflammatory cell model.
The results of this study demonstrated that shifting the
PUFA supply from 𝜔-6 to 𝜔-3 decreased the release of
proinflammatory cytokines and PGE
2
in human alveolar cells
challenged with BALF of ARDS patients. Moreover, these
data confirmed our previous finding that a predominance of
AA in PUFA supply determined amore aggressive proinflam-
matory response. Finally, these data provide a contribution to
support the biochemical basis for current recommendations
[57–60] to shift the lipid supply from 𝜔-6 to 𝜔-3 PUFA in the
nutrition support of ARDS patients.
In conclusion, there are good experimental evidence and
convincing rationale according to the𝜔-3 PUFA use in ARDS
patients [61]; however, questions still remain to be answered
regarding the in vivo effects of these PUFAs.
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